Anne Bjerg Nielsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne Bjerg Nielsen has a total of 197 co-authors. Here are the top co-authors by number of shared publications:
- Tor Biering-Sørensen
Department of Cardiology, Copenhagen University Hospital–Herlev and Gentofte, 2900 Hellerup, Denmark
11 shared publications - Lisa Steen Duus
Department of Cardiology, Copenhagen University Hospital – Herlev and Gentofte, Copenhagen, Denmark
10 shared publications - Niklas Dyrby Johansen
Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark
10 shared publications - Anne Marie Reimer Jensen
Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark; Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
8 shared publications Daniel Modin
Department of Cardiology, Copenhagen University Hospital – Herlev and Gentofte , Copenhagen
8 shared publicationsKristoffer Grundtvig Skaarup
8 shared publications
Latest Publications
- 16 October 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Effect of colchicine on arterial stiffness in patients with hypertension: the COlchicine HypERtENsion Trial (COHERENT)
Aims: This trial investigated whether colchicine, an anti-inflammatory treatment, affects cardiovascular structure and function, assessed by arterial stiffness, blood pressure, and biochemistry, compared with placebo. Methods and results: COHERENT was a randomized, double-blind, placebo-controlled trial of the effects of colchicine on arterial stiffness in adults with pharmacologically treated hypertension without cardiovascular disease. Eligible patients were randomized 1:1 to colchicine 0.5 mg daily or placebo for 6 months. Assessment of arterial stiffness, echocardiography, and biomarker measurement were performed at baseline and 6 months. The primary endpoint was change in carotid-femoral pulse wave velocity (cfPWV). Secondary endpoints included change in blood pressure (BP), left ventricular mass index, as well as change in cardiac and inflammatory biomarkers. Of 183 screened, 150 were randomized (75 per group). The mean age was 64.5 (±8.0) years, 53 (35.3%) were female, and mean systolic blood pressure was 140.3 (±16.5) mmHg. At 6 months, cfPWV did not differ between groups [between-group difference in ΔcfPWV −0.1 m/s, 95% confidence interval (CI): −0.5 to 0.3 m/s, P = 0.53]. Office systolic BP decreased significantly more in the placebo group than in the colchicine group (between-group difference in Δoffice systolic BP 5.7 mmHg, 95% CI: 1.0 to 10.5 mmHg, P = 0.018). hsCRP decreased significantly in the colchicine group compared with the placebo group (between-group difference in % change in hsCRP −39.8%, 95% CI: −59.1 to −11.4%, P = 0.010). The left ventricular mass index or cardiac biomarkers did not differ between groups. Conclusion: Six months of colchicine did not affect arterial stiffness in pharmacologically treated hypertension without cardiovascular disease. Colchicine significantly decreased hsCRP. Registration: ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT04916522
- 16 October 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Effect of colchicine on arterial stiffness in patients with hypertension: the COlchicine HypERtENsion Trial (COHERENT)
Aims: This trial investigated whether colchicine, an anti-inflammatory treatment, affects cardiovascular structure and function, assessed by arterial stiffness, blood pressure, and biochemistry, compared with placebo. Methods and results: COHERENT was a randomized, double-blind, placebo-controlled trial of the effects of colchicine on arterial stiffness in adults with pharmacologically treated hypertension without cardiovascular disease. Eligible patients were randomized 1:1 to colchicine 0.5 mg daily or placebo for 6 months. Assessment of arterial stiffness, echocardiography, and biomarker measurement were performed at baseline and 6 months. The primary endpoint was change in carotid-femoral pulse wave velocity (cfPWV). Secondary endpoints included change in blood pressure (BP), left ventricular mass index, as well as change in cardiac and inflammatory biomarkers. Of 183 screened, 150 were randomized (75 per group). The mean age was 64.5 (±8.0) years, 53 (35.3%) were female, and mean systolic blood pressure was 140.3 (±16.5) mmHg. At 6 months, cfPWV did not differ between groups [between-group difference in ΔcfPWV −0.1 m/s, 95% confidence interval (CI): −0.5 to 0.3 m/s, P = 0.53]. Office systolic BP decreased significantly more in the placebo group than in the colchicine group (between-group difference in Δoffice systolic BP 5.7 mmHg, 95% CI: 1.0 to 10.5 mmHg, P = 0.018). hsCRP decreased significantly in the colchicine group compared with the placebo group (between-group difference in % change in hsCRP −39.8%, 95% CI: −59.1 to −11.4%, P = 0.010). The left ventricular mass index or cardiac biomarkers did not differ between groups. Conclusion: Six months of colchicine did not affect arterial stiffness in pharmacologically treated hypertension without cardiovascular disease. Colchicine significantly decreased hsCRP. Registration: ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT04916522
- Open Access
- 6 October 2026
- Published by Elsevier in The Lancet Healthy Longevity
- Vol. 7 (9)
RSV prefusion F vaccine effectiveness in older adults with immunosuppression: a prespecified analysis of the DAN-RSV trial
- 6 October 2026
- Published by Elsevier in The Lancet Healthy Longevity
- Vol. 7 (9)
Open AccessRSV prefusion F vaccine effectiveness in older adults with immunosuppression: a prespecified analysis of the DAN-RSV trial
- Open Access
- 17 September 2026
- Published by Elsevier in The Lancet Healthy Longevity
- Vol. 7 (8)
Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2
- 17 September 2026
- Published by Elsevier in The Lancet Healthy Longevity
- Vol. 7 (8)
Open AccessEffectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2
- Open Access
- 28 August 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Effectiveness of high-dose vs. standard-dose influenza vaccine against venous thromboembolic events: a post hoc analysis of the DANFLU-2 trial
Trial registration Clinicaltrials.gov: NCT05517174
- 28 August 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
Open AccessEffectiveness of high-dose vs. standard-dose influenza vaccine against venous thromboembolic events: a post hoc analysis of the DANFLU-2 trial
Trial registration Clinicaltrials.gov: NCT05517174
- 1 November 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (11)
High-Dose Versus Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 Trial
BACKGROUND: Influenza contributes substantially to disease burden in individuals with heart failure (HF) and is an established trigger of cardiovascular and HF events. Standard-dose inactivated influenza vaccine (SD-IIV) is recommended for HF, though immune responses may be attenuated. High-dose inactivated influenza vaccine (HD-IIV) was developed to enhance immunogenicity, but its effectiveness compared with SD-IIV against hospitalization for influenza and cardiovascular disease by HF status remains uncertain. METHODS: This was a prespecified analysis of a pragmatic, prospective, individually randomized, open-label trial with registry-based end point-evaluation conducted in Denmark across the 2022/2023 to 2024/2025 influenza seasons. Citizens ≥65 years were randomized 1:1 to HD-IIV or SD-IIV. Outcomes included hospitalization for influenza-related illness, laboratory-confirmed influenza, any cardiovascular disease, cardio-respiratory disease, and HF, assessed by HF status. Effect of HD-IIV versus SD-IIV in reducing risk of outcomes assessed was expressed as risk ratios. RESULTS: The trial randomized 332 438 participants (48.6% female; mean age, 73.7±5.8 years), including 10 410 with HF at baseline (27.4% female; mean age, 76.0±6.3 years). Overall, HD-IIV was associated with a statistically significant lower incidence of hospitalization for influenza-related illness, laboratory-confirmed influenza, cardio-respiratory disease, cardiovascular disease, and HF compared with SD-IIV. In participants with HF, effect estimates were similar: risk ratio for influenza-related hospitalization was 0.48 (95% CI, 0.20–1.06; P interaction =0.64), for laboratory-confirmed influenza hospitalization 0.55 (95% CI, 0.29–1.02; P interaction =0.59), for cardio-respiratory hospitalization 0.89 (95% CI, 0.77–1.02; P interaction =0.34), for cardiovascular hospitalization 0.86 (95% CI, 0.72–1.02; P interaction =0.34), and for HF hospitalization 0.82 (95% CI, 0.61–1.11; P interaction =0.83). Findings were consistent across HF subgroups by disease duration, recency of hospitalization, most recent NT-proBNP (N-terminal pro-B-type natriuretic peptide), and presence of device therapy. CONCLUSIONS: In this prespecified exploratory analysis of the largest individually randomized influenza vaccine trial ever conducted, HD-IIV was associated with lower rates of influenza and cardiovascular hospitalizations compared with SD-IIV, with effect estimates similar across HF status at baseline and HF subgroups. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: https://clinicaltrials.gov/study/NCT05517174 .
- 1 November 2025
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (11)
High-Dose Versus Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 Trial
BACKGROUND: Influenza contributes substantially to disease burden in individuals with heart failure (HF) and is an established trigger of cardiovascular and HF events. Standard-dose inactivated influenza vaccine (SD-IIV) is recommended for HF, though immune responses may be attenuated. High-dose inactivated influenza vaccine (HD-IIV) was developed to enhance immunogenicity, but its effectiveness compared with SD-IIV against hospitalization for influenza and cardiovascular disease by HF status remains uncertain. METHODS: This was a prespecified analysis of a pragmatic, prospective, individually randomized, open-label trial with registry-based end point-evaluation conducted in Denmark across the 2022/2023 to 2024/2025 influenza seasons. Citizens ≥65 years were randomized 1:1 to HD-IIV or SD-IIV. Outcomes included hospitalization for influenza-related illness, laboratory-confirmed influenza, any cardiovascular disease, cardio-respiratory disease, and HF, assessed by HF status. Effect of HD-IIV versus SD-IIV in reducing risk of outcomes assessed was expressed as risk ratios. RESULTS: The trial randomized 332 438 participants (48.6% female; mean age, 73.7±5.8 years), including 10 410 with HF at baseline (27.4% female; mean age, 76.0±6.3 years). Overall, HD-IIV was associated with a statistically significant lower incidence of hospitalization for influenza-related illness, laboratory-confirmed influenza, cardio-respiratory disease, cardiovascular disease, and HF compared with SD-IIV. In participants with HF, effect estimates were similar: risk ratio for influenza-related hospitalization was 0.48 (95% CI, 0.20–1.06; P interaction =0.64), for laboratory-confirmed influenza hospitalization 0.55 (95% CI, 0.29–1.02; P interaction =0.59), for cardio-respiratory hospitalization 0.89 (95% CI, 0.77–1.02; P interaction =0.34), for cardiovascular hospitalization 0.86 (95% CI, 0.72–1.02; P interaction =0.34), and for HF hospitalization 0.82 (95% CI, 0.61–1.11; P interaction =0.83). Findings were consistent across HF subgroups by disease duration, recency of hospitalization, most recent NT-proBNP (N-terminal pro-B-type natriuretic peptide), and presence of device therapy. CONCLUSIONS: In this prespecified exploratory analysis of the largest individually randomized influenza vaccine trial ever conducted, HD-IIV was associated with lower rates of influenza and cardiovascular hospitalizations compared with SD-IIV, with effect estimates similar across HF status at baseline and HF subgroups. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: https://clinicaltrials.gov/study/NCT05517174 .